Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Phase 3
Not yet recruiting
- Conditions
- Somatostatin Receptor Positive (SSTR+)Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
- Interventions
- Radiation: [177Lu]Lu-DOTA-TATE
- First Posted Date
- 2025-01-20
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 240
- Registration Number
- NCT06784752
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Phase 2
Recruiting
- Conditions
- Prostate Cancer
- Interventions
- Drug: Investigators choice of SoC
- First Posted Date
- 2025-01-17
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 432
- Registration Number
- NCT06780670
- Locations
- 🇸🇬
Novartis Investigative Site, Singapore, Singapore
Leqvio rPMS (Regulatory Post-Marketing Surveillance in Korea)
Not yet recruiting
- Conditions
- Primary Hypercholesterolemia or Mixed Dyslipidemia
- First Posted Date
- 2025-01-13
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1500
- Registration Number
- NCT06770543
Effectiveness of Ofatumumab in Real-world Practice
Completed
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2025-01-07
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 779
- Registration Number
- NCT06760624
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
- First Posted Date
- 2024-12-27
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT06751238
- Locations
- 🇺🇸
Legacy Emanuel Research Hospital Portland, Portland, Oregon, United States
🇺🇸Texas Arthritis Center, El Paso, Texas, United States
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
Phase 3
Recruiting
- Conditions
- Generalized Myasthenia Gravis
- Interventions
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 180
- Registration Number
- NCT06744920
- Locations
- 🇺🇸
Dent Neurological Institute, Buffalo, New York, United States
Real World Effectiveness, Persistence, Tolerability, and Safety of Ofatumumab in Clinical Practice
Completed
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2024-12-17
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 175
- Registration Number
- NCT06737419
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS
Phase 4
Recruiting
- Conditions
- Relapsing Remitting Multiple Sclerosis (RRMS)
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 224
- Registration Number
- NCT06733922
- Locations
- 🇨🇦
Novartis Investigative Site, Quebec, Canada
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid Tumors
- Interventions
- First Posted Date
- 2024-12-10
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 280
- Registration Number
- NCT06726148
- Locations
- 🇸🇬
Novartis Investigative Site, Singapore, Singapore
A Real-world Study of Tuberculosis Incidence in AS, PsA, or PsO Patients Treated With Secukinumab in Brazil
Terminated
- Conditions
- Tuberculosis
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 152
- Registration Number
- NCT06715254
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
© Copyright 2025. All Rights Reserved by MedPath